Janssen Pharmaceutical, Inc., the division of Johnson & Johnson that developed and marketed the Risperdal antipsychotic medication, has settled a Risperdal lawsuit brought by the State of Montana for $5.9 million.  The Attorney General of Montana had initiated a lawsuit against the manufacturer in 2008 alleging that the company promoted the drug as safe despite having knowledge of a range of dangerous side effects, including diabetes. The settlement terms require Johnson & Johnson to cease any misleading marketing of Risperdal, and... Read More